» Articles » PMID: 35313903

The Impact of an Integrated Safer Use Space and Safer Supply Program on Non-fatal Overdose Among Emergency Shelter Residents During a COVID-19 Outbreak: a Case Study

Overview
Journal Harm Reduct J
Publisher Biomed Central
Specialties Pharmacology
Psychiatry
Date 2022 Mar 22
PMID 35313903
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Opioid-related harms, including fatal and non-fatal overdoses, rose dramatically during the COVID-19 pandemic and presented unique challenges during outbreaks in congregate settings such as shelters. People who are deprived of permanent housing have a high prevalence of substance use and substance use disorders, and need nimble, rapid, and portable harm reduction interventions to address the harms of criminalized substance use in an evidence-based manner.

Case Study: In February 2021, a COVID-19 outbreak was declared at an emergency men's shelter in Hamilton, Ontario, Canada. Building on pre-existing relationships, community and hospital-based addictions medicine providers and a local harm reduction group collaborated to establish a shelter-based opioid agonist treatment and safer supply program, and a volunteer run safer drug use space that also distributed harm reduction supplies. In the 4 weeks preceding the program, the rate of non-fatal overdoses was 0.93 per 100 nights of shelter bed occupancy. During the 26 days of program operation, there were no overdoses in the safer use space and the rate of non-fatal overdoses in the shelter was 0.17 per 100 nights of shelter bed occupancy. The odds ratio of non-fatal overdose pre-intervention to during intervention was 5.5 (95% CI 1.63-18.55, p = 0.0059). We were not able to evaluate the impact of providing harm reduction supplies and did not evaluate the impact of the program on facilitating adherence to public health isolation and quarantine orders. The program ended as the outbreak waned, as per the direction from the shelter operator.

Conclusions: There was a significant reduction in the non-fatal overdose rate after the safer drug use and safer supply harm reduction program was introduced. Pre-existing relationships between shelter providers, harm reduction groups, and healthcare providers were critical to implementing the program. This is a promising approach to reducing harms from the criminalization of substance use in congregate settings, particularly in populations with a higher prevalence of substance use and substance use disorders.

Citing Articles

Perceived impacts of North Americas first de-medicalized safer supply program.

Kalicum J, Nyx E, Kennedy M, Kerr T Subst Abuse Treat Prev Policy. 2025; 20(1):11.

PMID: 40065329 PMC: 11892302. DOI: 10.1186/s13011-025-00642-0.


Using illicit drugs alone in Vancouver, Canada: a gender-based analysis.

Gallant K, Hayashi K, Sayre E, Choi J, Mansoor M, Kerr T Subst Abuse Treat Prev Policy. 2025; 20(1):9.

PMID: 39987447 PMC: 11846176. DOI: 10.1186/s13011-025-00637-x.


Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis.

Schmidt R, Guta A, Rai N, Sereda A, OReilly E, Hales J Can J Public Health. 2024; .

PMID: 39658780 DOI: 10.17269/s41997-024-00979-2.


Clinicians' Perspectives and an Ethical Analysis of Safer Supply Opioid Prescribing.

Bird K, Genuis Q, Ickowicz S J Bioeth Inq. 2024; .

PMID: 39466553 DOI: 10.1007/s11673-024-10387-3.


Access and barriers to safer supply prescribing during a toxic drug emergency: a mixed methods study of implementation in British Columbia, Canada.

Urbanoski K, van Roode T, Selfridge M, Hogan K, Fraser J, Lock K Subst Abuse Treat Prev Policy. 2024; 19(1):44.

PMID: 39285270 PMC: 11406709. DOI: 10.1186/s13011-024-00625-7.


References
1.
Bonn M, Palayew A, Bartlett S, Brothers T, Touesnard N, Tyndall M . Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply. J Stud Alcohol Drugs. 2020; 81(5):556-560. View

2.
Roxburgh A, Jauncey M, Day C, Bartlett M, Cogger S, Dietze P . Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. Harm Reduct J. 2021; 18(1):20. PMC: 7887539. DOI: 10.1186/s12954-021-00471-x. View

3.
Jones C, Bekheet F, Park J, Alexander G . The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms. Epidemiol Rev. 2021; 42(1):154-166. PMC: 9200066. DOI: 10.1093/epirev/mxaa011. View

4.
DiGennaro C, Garcia G, Stringfellow E, Wakeman S, Jalali M . Changes in characteristics of drug overdose death trends during the COVID-19 pandemic. Int J Drug Policy. 2021; 98:103392. PMC: 9759694. DOI: 10.1016/j.drugpo.2021.103392. View

5.
Hwang S . Homelessness and health. CMAJ. 2001; 164(2):229-33. PMC: 80688. View